Free tool
FAERS Monitor: Ovidrel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021149 or its brand name (Ovidrel, Choriogonadotropin Alfa). Reports on generic versions are filed under their own applications.
Reports
1,163
Serious
924
79% of reports
Hospitalization
583
Death reported
25
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ovarian hyperstimulation syndrome448
- ascites83
- abdominal distension74
- abdominal pain70
- nausea62
- off label use62
- dyspnoea51
- pleural effusion48
- abortion spontaneous46
- maternal exposure during pregnancy40
- headache38
- vomiting37
- maternal exposure before pregnancy32
- abdominal pain lower31
- dizziness30
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 4 |
| 2006 | 6 |
| 2007 | 16 |
| 2008 | 8 |
| 2009 | 11 |
| 2010 | 10 |
| 2011 | 18 |
| 2012 | 27 |
| 2013 | 30 |
| 2014 | 26 |
| 2015 | 11 |
| 2016 | 24 |
| 2017 | 15 |
| 2018 | 32 |
| 2019 | 64 |
| 2020 | 43 |
| 2021 | 84 |
| 2022 | 163 |
| 2023 | 150 |
| 2024 | 175 |
| 2025 | 114 |
| 2026 | 127 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,996 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ovarian hyperstimulation syndromeSignal | 448 | 4302.3 | 3949.8 | 1,553,286 |
| maternal exposure before pregnancySignal | 32 | 85.1 | 60.4 | 2,565 |
| ascitesSignal | 83 | 51.2 | 41.6 | 4,030 |
| abdominal pain lowerSignal | 31 | 22.2 | 15.7 | 607 |
| abortion spontaneousSignal | 46 | 20.8 | 15.7 | 847 |
| pleural effusionSignal | 48 | 14.3 | 10.8 | 581 |
| abdominal distensionSignal | 74 | 12.8 | 10.3 | 799 |
| maternal exposure during pregnancySignal | 40 | 8.1 | 6.0 | 244 |
| abdominal painSignal | 70 | 5.4 | 4.3 | 252 |
| dyspnoea | 51 | 1.6 | 1.2 | 12 |
| vomiting | 37 | 1.4 | 1.0 | 4 |
| nausea | 62 | 1.4 | 1.1 | 7 |
| off label use | 62 | 1.3 | 1.0 | 4 |
| headache | 38 | 1.1 | 0.8 | 0 |
| dizziness | 30 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.